Profund Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Profund Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-68	Closed	-$47K	–	1601
2014 Q1	$47K	Buy	+68	New	+$45.6K	﹤0.01%	1568

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BGA

Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Profund Advisors's TCRT Position: Q2 2014 in Review

Profund Advisors sold out of Alaunos Therapeutics (TCRT) in Q2 2014, closing a stake of 68 shares — an estimated $47K sold.

Profund Advisors first reported a position in TCRT in Q1 2014 and held it in 1 quarter. The position peaked at $47K in Q1 2014. 92 funds tracked by Wall St. Rank hold TCRT as of Q2 2014.

Profund Advisors reported no remaining Alaunos Therapeutics position as of Q2 2014 after selling out during the quarter.
Profund Advisors sold 68 Alaunos Therapeutics shares in Q2 2014, an estimated $47K.
Profund Advisors first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 1 quarter.
Profund Advisors's Alaunos Therapeutics position peaked at $47K in Q1 2014.
92 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2014.

Based on Profund Advisors's 13F filing for Q2 2014, filed 8 Aug 2014.